Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3350/cmh.2024.0916 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
READER'S FORUM.
Korean J Orthod
January 2025
Institute of Craniofacial Deformity, College of Dentistry, Yonsei University, Seoul, Korea.
Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes.
Biomark Res
January 2025
Laboratory of Cellular Therapy, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena, Modena, 41124, Italy.
Emerging evidence highlights the key role of microRNA (miR)-21 in cell-to-cell communication and tumorigenesis. However, limited knowledge exists on the levels and clinical meaning of miR-21 in extracellular vesicles (EVs) of patients with breast cancer (BC). We assessed EV-derived miR-21 levels in one hundred women: 30 with early BC (EBC), 30 with metastatic BC on treatment progression (MBC), 30 cancer survivors on follow-up (FU) and 10 healthy donors (HD) as age- and body mass index (BMI)-matched controls.
View Article and Find Full Text PDFImpact of underlying diseases and complications on COVID-19 mortality in South Korea: analysis of national health insurance service data.
Arch Public Health
January 2025
Department of Health Administration, College of Health Science, Dankook University, 119 Dandaero, Dongnam-gu, Cheonan city, Chungcheongnam-do, 31116, Republic of Korea.
Background: Comorbidities or complications significantly influence coronavirus disease-2019 (COVID-19) severity and mortality risk. Therefore, this study aimed to compare treatment outcomes of COVID-19 inpatients by underlying diseases or complications.
Method: Data on COVID-19 patients from the National Health Insurance Service customized research database were analyzed while focusing on eight underlying diseases and complications: diabetes, hypertension, heart disease, kidney disease, liver disease, dementia, depression, and respiratory disease.
Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma.
Biomark Res
January 2025
Incyte Corporation, Wilmington, DE, USA.
Potential CD19 antigen loss following CD19-directed therapy has raised concerns over sequential use of these therapies. Tafasitamab, a CD19-targeting immunotherapy, combined with lenalidomide, is approved for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) treatment in adults ineligible for autologous stem cell transplantation. This retrospective analysis examined characteristics and outcomes of adults with R/R DLBCL who received tafasitamab preceding CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy in a real-world setting.
View Article and Find Full Text PDFWT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome.
J Hematol Oncol
January 2025
Center for Cell Therapy & Regenerative Medicine (CCRG), Antwerp University Hospital (UZA), Edegem, Belgium.
Cell therapies, including tumor antigen-loaded dendritic cells used as therapeutic cancer vaccines, offer treatment options for patients with malignancies. We evaluated the feasibility, safety, immunogenicity, and clinical activity of adjuvant vaccination with Wilms' tumor protein (WT1) mRNA-electroporated autologous dendritic cells (WT1-mRNA/DC) in a single-arm phase I/II clinical study of patients with advanced solid tumors receiving standard therapy. Disease status and immune reactivity were evaluated after 8 weeks and 6 months.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!